{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:52:05Z","timestamp":1791996725452,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024KY636"],"award-info":[{"award-number":["2024KY636"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502781"],"award-info":[{"award-number":["82502781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.intimp.2026.116949","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:29:29Z","timestamp":1780532969000},"page":"116949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["PARD6G mediates resistance to PD-1 immune checkpoint blockade in head and neck squamous cell carcinoma"],"prefix":"10.1016","volume":"184","author":[{"given":"Wei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqian","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116949_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.116949_bb0010","series-title":"International agency for research on cancer (IARC), global cancer observatory: globocan 2022","year":"2024"},{"key":"10.1016\/j.intimp.2026.116949_bb0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/cancers13020338","article-title":"Recent advances and future directions in clinical management of head and neck squamous cell carcinoma","volume":"13","author":"Muzaffar","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116949_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.oraloncology.2019.01.018","article-title":"The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review","volume":"90","author":"Ghanizada","year":"2019","journal-title":"Oral Oncol."},{"key":"10.1016\/j.intimp.2026.116949_bb0025","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3389\/fimmu.2020.01721","article-title":"The evolving landscape of PD-1\/PD-L1 pathway in head and neck cancer","volume":"11","author":"Qiao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116949_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202516348","article-title":"PD-L1 on tumor-derived extracellular vesicles induces CD8+ T cell terminal exhaustion and mediates anti-PD-1 resistance in head and neck squamous cell carcinoma","volume":"13","author":"Fang","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.intimp.2026.116949_bb0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00262-025-04233-7","article-title":"Immune biomarkers for head and neck cancer","volume":"75","author":"Sobhani","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.116949_bb0040","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1056\/NEJMc1508163","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"373","author":"Chan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116949_bb0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: An analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116949_bb0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: Results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.116949_bb0055","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.intimp.2026.116949_bb0060","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.116949_bb0065","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116949_bb0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumors with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.116949_bb0075","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.intimp.2026.116949_bb0080","doi-asserted-by":"crossref","first-page":"eaam9899","DOI":"10.1126\/scisignal.aam9899","article-title":"Structural basis for the interaction between the cell polarity proteins Par3 and Par6","volume":"11","author":"Renschler","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.intimp.2026.116949_bb0085","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.tcb.2011.06.005","article-title":"Epithelial organization, cell polarity and tumorigenesis","volume":"21","author":"McCaffrey","year":"2011","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.intimp.2026.116949_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159881","article-title":"Disruption of the Cdc42\/Par6\/aPKC or Dlg\/Scrib\/Lgl polarity complex promotes epithelial proliferation via overlapping mechanisms","volume":"11","author":"Schimizzi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2026.116949_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2307\/2532740","article-title":"Maximally selected rank statistics","volume":"48","author":"Lausen","year":"1992","journal-title":"Biometrics"},{"key":"10.1016\/j.intimp.2026.116949_bb0100","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2026.116949_bb0105","first-page":"396","article-title":"Differential analysis of gene expression profiles in hepatocellular carcinoma patients with high and low levels of alpha-fetoprotein","volume":"42","author":"Wang","year":"2020","journal-title":"Zhonghua Chinese Journal of Oncology."},{"key":"10.1016\/j.intimp.2026.116949_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.intimp.2026.116949_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101977","article-title":"Biomarkers for immunotherapy response in head and neck cancer","volume":"84","author":"Gavrielatou","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2026.116949_bb0120","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","article-title":"Adaptive immune resistance at the tumor site: mechanisms and therapeutic opportunities","volume":"21","author":"Kim","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.116949_bb0125","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116949_bb0130","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116949_bb0135","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116949_bb0140","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jtho.2023.03.012","article-title":"Classification of tumor immune microenvironment according to programmed death-ligand 1 expression and immune infiltration predicts response to immunotherapy plus chemotherapy in advanced patients with NSCLC","volume":"18","author":"Sun","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.116949_bb0145","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.7150\/thno.45219","article-title":"Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.116949_bb0150","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/cas.14022","article-title":"Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes","volume":"110","author":"Akazawa","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2026.116949_bb0155","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.7150\/ijbs.70137","article-title":"MGP promotes CD8+ T cell exhaustion by activating the NF-\u03baB pathway leading to liver metastasis of colorectal cancer","volume":"18","author":"Rong","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2026.116949_bb0160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116949_bb0165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-023-01405-9","article-title":"Exploiting RIG-I-like receptor pathway for cancer immunotherapy","volume":"16","author":"Jiang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116949_bb0170","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.116949_bb0175","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.116949_bb0180","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/biomedicines13040930","article-title":"CD8+ T cell subsets as biomarkers for predicting checkpoint therapy outcomes in cancer immunotherapy","volume":"13","author":"Casalegno Gardu\u00f1o","year":"2025","journal-title":"Biomedicines"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926007952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926007952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:29:14Z","timestamp":1791995354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926007952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S1567576926007952"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116949","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARD6G mediates resistance to PD-1 immune checkpoint blockade in head and neck squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116949"}}